BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 2757026)

  • 1. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who should receive recombinant human erythropoietin?
    Van Stone JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for recombinant human erythropoietin therapy.
    Eschbach JW; Adamson JW
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to recombinant human erythropoietin therapy: a real clinical entity?
    Stivelman JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):8-11. PubMed ID: 2669085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin].
    Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA
    Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
    Fishbane S; Lynn RI
    Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron metabolism and iron substitution during erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Clin Investig; 1994; 72(6 Suppl):S11-5. PubMed ID: 7950165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical considerations of recombinant human erythropoietin therapy.
    Paganini EP; Latham D; Abdulhadi M
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
    Hotta T; Ogawa H; Saito A; Ito A
    Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.